BRIEF-Gilead receives approval in Canada for Vosevi for re-treatment of certain patients with chronic hep c virus infection
August 17, 2017 at 06:05 AM EDT
* Gilead receives approval in Canada for Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis c virus (HCV) infection Source text for Eikon: Further company coverage: